Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study)

PURPOSE: The CIGMA study investigated a novel human polyclonal antibody preparation (trimodulin) containing ~ 23% immunoglobulin (Ig) M, ~ 21% IgA, and ~ 56% IgG as add-on therapy for patients with severe community-acquired pneumonia (sCAP). METHODS: In this double-blind, phase II study (NCT01420744...

Descripción completa

Detalles Bibliográficos
Autores principales: Welte, Tobias, Dellinger, R. Phillip, Ebelt, Henning, Ferrer, Miguel, Opal, Steven M., Singer, Mervyn, Vincent, Jean-Louis, Werdan, Karl, Martin-Loeches, Ignacio, Almirall, Jordi, Artigas, Antonio, Ignacio Ayestarán, Jose, Nuding, Sebastian, Ferrer, Ricard, Sirgo Rodríguez, Gonzalo, Shankar-Hari, Manu, Álvarez-Lerma, Francisco, Riessen, Reimer, Sirvent, Josep-Maria, Kluge, Stefan, Zacharowski, Kai, Bonastre Mora, Juan, Lapp, Harald, Wöbker, Gabriele, Achtzehn, Ute, Brealey, David, Kempa, Axel, Sánchez García, Miguel, Brederlau, Jörg, Kochanek, Matthias, Reschreiter, Henrik Peer, Wise, Matthew P., Belohradsky, Bernd H., Bobenhausen, Iris, Dälken, Benjamin, Dubovy, Patrick, Langohr, Patrick, Mayer, Monika, Schüttrumpf, Jörg, Wartenberg-Demand, Andrea, Wippermann, Ulrike, Wolf, Daniele, Torres, Antoni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Seven-Day Profile Publication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924663/
https://www.ncbi.nlm.nih.gov/pubmed/29632995
http://dx.doi.org/10.1007/s00134-018-5143-7

Ejemplares similares

Ejemplares similares